Immunome Inc. Files Definitive Proxy Statement for June 10 Meeting

Ticker: IMNM · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1472012

Immunome Inc. DEF 14A Filing Summary
FieldDetail
CompanyImmunome Inc. (IMNM)
Form TypeDEF 14A
Filed DateApr 24, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

TL;DR

Immunome's proxy statement is out for the June 10 meeting - vote your shares!

AI Summary

Immunome Inc. filed its definitive proxy statement on April 24, 2025, for its annual meeting of stockholders scheduled for June 10, 2025. The filing, designated as DEF 14A, outlines the company's governance and proposals to be voted on by shareholders. Key details regarding executive compensation, director elections, and other corporate matters will be presented.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing, not indicating any immediate financial or operational risks.

Key Numbers

  • 18 — Public Documents (Number of documents included in the filing)

Key Players & Entities

  • Immunome Inc. (company) — Registrant
  • 0001140361-25-015421 (filing_id) — Accession Number
  • 20250424 (date) — Filing Date
  • 20250610 (date) — Meeting Date

FAQ

What is the purpose of a DEF 14A filing?

A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing details on matters to be voted upon.

When is Immunome Inc.'s annual meeting of stockholders?

Immunome Inc.'s annual meeting of stockholders is scheduled for June 10, 2025.

What is the filing date of this proxy statement?

This definitive proxy statement was filed on April 24, 2025.

What is the company's SIC code?

Immunome Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Where is Immunome Inc. headquartered?

Immunome Inc.'s business address is located at 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding Immunome Inc. (IMNM).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.